Medigene AG: Notification of Loss of Half of the Share Capital According to § 92 AktG and Cash Runway Amendment

Planegg/Martinsried (pta045/28.03.2025/20:00 UTC+1)

The Executive Management Board of Medigene AG (Medigene or the "Company", FWB: MDG1, Prime Standard) announces that, in the exercise of its due discretion, it must be assumed that there is a loss of more than half of the share capital.

In accordance with § 92 (1) of the German Stock Corporation Act (AktG), the Executive Management Board is obligated to call a shareholder meeting without delay, during which the Executive Management Board must formally report the loss of half of the share capital. Accordingly, the Company will timely invite shareholders to an Extraordinary General Meeting.

The Executive Management Board also announces the adjustment of the cash reach from July 2025 to May 2025 due to milestone payments and income from contractual obligations not received. The Company's cash runway includes potential future milestone payments from existing partnerships that are highly likely to materialize. It does not include potential milestone payments from or future/new partnerships or transactions as the occurrence of such payments or their timing and size largely depend on third parties and cannot be controlled or influenced by Medigene (see Annual Report 2023).

Medigene's management continues to work to maintain the Company's operations by obtaining additional financing.

The Company continues to maintain its 2024 financial guidance for R&D expenses and revenues.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A40ESG2 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate